Eyebright Medical Technology (Beijing) Co., Ltd.

About Eyebright Medical Technology (Beijing) Co., Ltd.

Eyebright Medical Technology (Beijing) Co., Ltd., also known as 爱博诺德, was founded on April 21, 2010, and is headquartered at No. 9 Xingchang Road, Changping District Technology Park, Beijing. The company is a high-tech enterprise and a national "Specialized, Refined, Distinctive, and Innovative" Little Giant. It was established by Dr. Jiangbing Xie, a state-appointed expert and overseas returnee. In July 2020, Eyebright was listed on the STAR Market of the Shanghai Stock Exchange under the stock code 688050. The company focuses on R&D, production, sales, and services for ophthalmic medical devices across three main fields: ophthalmic surgery, myopia prevention and control, and vision care.

Core Business and Products

Eyebright's core products include:

• Artificial Intraocular Lenses (IOLs): Introduced China's first foldable aspheric refractive IOL in 2014. The Purite series covers spherical, aspheric, and toric IOLs for cataract surgery. The Puritech series features preloaded IOLs, while the Quan Shi series offers premium multifocal IOLs. In October 2022, its aspheric diffractive multifocal IOL was approved in china, and in February 2025, its aspheric refractive pseudophakic IOL received NMPA approval.

• Orthokeratology Lenses (OK Lenses): The Purotong OK lens was approved by the NMPA in 2019 and is now widely used in over 2,000 hospitals. In August 2025, its hard gas-permeable OK lens for corneal reshaping gained NMPA Class III certification.

• Other Products: Include myopia control lenses, colored contact lenses, surgical instruments, and care solutions. In 2022, it launched China’s first full-vision multifocal IOL (Purotong Quan Shi), followed by an OK lens care solution in 2024.

Market Position and Performance

Eyebright leads the domestic market for artificial IOLs and has established strong recognition for its OK lenses. In 2024, revenue reached 1.41 billion yuan, up 48.22% year-on-year, with net profit of 387 million yuan, up 27.36%. In Q1 2025, revenue was 357 million yuan (26.42% YoY growth), and net profit was 109 million yuan (25.19% YoY growth). R&D investment grew at a CAGR of 22.55% from 2020 to 2024, reaching 233.7 million yuan in 2024, or 16.56% of total revenue.

Development Strategy and Vision

Eyebright aims to build a full portfolio of ophthalmic products including implantable consumables, surgical instruments, surgical equipment, vision care, and ophthalmic formulations. Its strategic fields cover cataracts, refractive errors, glaucoma, and retinal diseases. The company’s vision is “Technology Illuminates Vision,” with a mission to deliver advanced global ophthalmic technologies, products, and services.

Contact Information

• Address: No. 9 Xingchang Road, Technology Park, Changping District, Beijing, China

• Phone: 010-89748322

• Fax: 010-89747942

• Email: investors@ebmedical.com